Level Four Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.98M Buy
10,034
+510
+5% +$226K 0.14% 180
2026
Q1
$4.25M Sell
9,524
-29
-0.3% -$13.5K 0.14% 190
2025
Q4
$4.33M Buy
9,553
+1,967
+26% +$848K 0.14% 188
2025
Q3
$2.97M Buy
7,586
+135
+2% +$56.4K 0.1% 224
2025
Q2
$3.32M Sell
7,451
-985
-12% -$454K 0.12% 204
2025
Q1
$4.09M Buy
8,436
+969
+13% +$452K 0.17% 170
2024
Q4
$3.01M Buy
7,467
+434
+6% +$201K 0.12% 193
2024
Q3
$3.35M Sell
7,033
-142
-2% -$68.2K 0.14% 182
2024
Q2
$3.36M Sell
7,175
-349
-5% -$151K 0.15% 183
2024
Q1
$3.06M Buy
7,524
+248
+3% +$105K 0.17% 147
2023
Q4
$2.96M Sell
7,276
-290
-4% -$107K 0.17% 148
2023
Q3
$2.63M Buy
7,566
+35
+0.5% +$12.2K 0.17% 150
2023
Q2
$2.65M Buy
7,531
+35
+0.5% +$11.8K 0.16% 146
2023
Q1
$2.36M Sell
7,496
-415
-5% -$124K 0.15% 155
2022
Q4
$2.28M Sell
7,911
-719
-8% -$219K 0.17% 145
2022
Q3
$2.5M Sell
8,630
-262
-3% -$75.4K 0.24% 109
2022
Q2
$2.51M Sell
8,892
-422
-5% -$113K 0.24% 118
2022
Q1
$2.43M Buy
9,314
+87
+0.9% +$20.6K 0.19% 137
2021
Q4
$2.03M Sell
9,227
-576
-6% -$112K 0.15% 154
2021
Q3
$1.78M Buy
+9,803
New +$1.91M 0.18% 134
2020
Q3
Sell
-865
Closed -$248K 586
2020
Q2
$248K Buy
+865
New +$235K 0.02% 495

Other funds holding VRTX

Level Four Advisory Services's VRTX Position: Q2 2026 in Review

Level Four Advisory Services increased its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, buying an estimated $226K and bringing the position to 10,034 shares worth $4.98M. The position accounts for 0.14% of the portfolio, ranked #180.

Level Four Advisory Services first reported a position in VRTX in Q2 2020 and has held it in 21 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Level Four Advisory Services held 10,034 shares of Vertex Pharmaceuticals worth $4.98M as of Q2 2026.
  • Level Four Advisory Services bought 510 Vertex Pharmaceuticals shares in Q2 2026, an estimated $226K.
  • Vertex Pharmaceuticals made up 0.14% of Level Four Advisory Services's portfolio in Q2 2026, its #180 holding.
  • Level Four Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Level Four Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.